The common AEs observed in this study were increased AST or ALT levels, thrombocytopenia, anemia, neutropenia, leukocytopenia, abnormal ECG, vomiting, nausea, and fatigue, which were similar to those reported in a previous study of chemotherapy and an anti-PD-1 antibody.8 Hematologic toxicity was the main grade 3 or higher AE in this study as well as the most common TEAE for toripalimab in a phase 3 study on advanced nasopharyngeal carcinoma.34 In the present study, dose modification was observed in six subjects and medication delay in ten subjects due to AEs. The gene discussed is GPT; the disease is Thrombocytopenia.